Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Fuji
Cipla
US Department of Justice
Covington
Fish and Richardson
Harvard Business School
US Army

Generated: August 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021168

« Back to Dashboard

NDA 021168 describes DEPAKOTE ER, which is a drug marketed by Abbvie and is included in one NDA. It is available from eight suppliers. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the DEPAKOTE ER profile page.

The generic ingredient in DEPAKOTE ER is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
Summary for 021168
Tradename:DEPAKOTE ER
Applicant:Abbvie
Ingredient:divalproex sodium
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 021168
Suppliers and Packaging for NDA: 021168
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168 NDA AbbVie Inc. 0074-3826 N 0074-3826-11
DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168 NDA AbbVie Inc. 0074-3826 N 0074-3826-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 500MG VALPROIC ACID
Approval Date:Aug 4, 2000TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 18, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Jun 18, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Jun 18, 2019Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021168

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
Accenture
QuintilesIMS
Farmers Insurance
Baxter
Cerilliant
Moodys
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.